Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Age Escalation / De-escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Radiation-attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults, Children and Infants, and Comparison With Non-attenuated Pf Sporozoites (PfSPZ Challenge) Administered Under Chloroquine Prophylaxis (PfSPZ-CVac Approach) for Efficacy Against Controlled Human Malaria Infection.

NCT02859350 is registered in ClinicalTrials.gov with Sanaria Inc. as lead sponsor.

NCT NCT02859350
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02859350 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Age Escalation / De-escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Radiation-attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults, Children and Infants, and Comparison With Non-attenuated Pf Sporozoites (PfSPZ Challenge) Administered Under Chloroquine Prophylaxis (PfSPZ-CVac Approach) for Efficacy Against Controlled Human Malaria Infection.
Lead sponsor
Sanaria Inc.
Phase
Phase 1
Overall status
Completed
Start date
November 30, 2016
Completion date
February 28, 2018
Enrollment
135 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

malaria